B细胞非霍奇金淋巴瘤-话题@MedSci

#B细胞非霍奇金淋巴瘤#

11篇内容 | 805人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2200517, encodeId=4727220051ea1, content=<a href='/topic/show?id=4e2640e283' target=_blank style='color:#2F92EE;'>#CAR-T细胞#</a> <a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a> <a href='/topic/show?id=650811382e21' target=_blank style='color:#2F92EE;'>#大 B 细胞淋巴瘤#</a>, objectTitle=NEJM Evid：新研究发现美国少数民族淋巴瘤患者在获得CAR-T细胞疗法方面的不平等, objectType=article, longId=823290, objectId=d8bc8232900c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240425/1714050254147_2185383.png, objectUrl=/article/show_article.do?id=d8bc8232900c, replyNumber=0, likeNumber=0, createdTime=昨天, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198987, encodeId=cc1e219898e0b, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a> <a href='/topic/show?id=0f11113466aa' target=_blank style='color:#2F92EE;'>#B-NHL#</a>, objectTitle=柳叶刀重磅综述：B细胞非霍奇金淋巴瘤, objectType=article, longId=821808, objectId=c5cc8218082e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=c5cc8218082e, replyNumber=0, likeNumber=8, createdTime=2024-04-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c5cc8218082e, moduleTitle=柳叶刀重磅综述：B细胞非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5cc8218082e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2180717, encodeId=2b782180e174a, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a> <a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=Mol Cancer：新型CAR-T细胞治疗AT101治疗复发或难治性B细胞非霍奇金淋巴瘤，客观缓解率91.7%！, objectType=article, longId=808750, objectId=a96d808e5065, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240110/c78414aa3c734f5c83af23aff25a5873.jpg, objectUrl=/article/show_article.do?id=a96d808e5065, replyNumber=0, likeNumber=36, createdTime=2024-01-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=a96d808e5065, moduleTitle=Mol Cancer：新型CAR-T细胞治疗AT101治疗复发或难治性B细胞非霍奇金淋巴瘤，客观缓解率91.7%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a96d808e5065)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1631080, encodeId=b4421631080f8, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, objectType=article, longId=728566, objectId=eb89e28566e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e28566e7, replyNumber=0, likeNumber=38, createdTime=2022-06-04, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e28566e7, moduleTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e28566e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631079, encodeId=e73c16310e913, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, objectType=article, longId=726862, objectId=923fe2686288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=923fe2686288, replyNumber=0, likeNumber=36, createdTime=2022-05-16, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=923fe2686288, moduleTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=923fe2686288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631078, encodeId=2deb16310e887, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=39, createdTime=2021-09-12, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631077, encodeId=3d0616310e766, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, objectType=article, longId=208782, objectId=0413208e8273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0413208e8273, replyNumber=0, likeNumber=35, createdTime=2021-03-22, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0413208e8273, moduleTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0413208e8273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631076, encodeId=629416310e6bd, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , objectType=article, longId=195309, objectId=a2e71953094c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e71953094c, replyNumber=0, likeNumber=40, createdTime=2020-06-06, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e71953094c, moduleTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e71953094c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631075, encodeId=a64116310e5ab, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, objectType=article, longId=191606, objectId=a4ff1916061e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4ff1916061e, replyNumber=0, likeNumber=30, createdTime=2020-04-08, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4ff1916061e, moduleTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4ff1916061e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631074, encodeId=375716310e4d3, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, objectType=article, longId=185002, objectId=956e185002ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956e185002ad, replyNumber=0, likeNumber=39, createdTime=2019-12-22, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956e185002ad, moduleTitle=Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956e185002ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631073, encodeId=e96216310e318, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=AP&T：慢性乙型肝炎会增加B细胞非霍奇金淋巴瘤和多发性骨髓瘤发生风险, objectType=article, longId=160233, objectId=01b116023331, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01b116023331, replyNumber=0, likeNumber=43, createdTime=2019-02-18, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01b116023331, moduleTitle=AP&T：慢性乙型肝炎会增加B细胞非霍奇金淋巴瘤和多发性骨髓瘤发生风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01b116023331)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631072, encodeId=18bb16310e220, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, objectType=article, longId=134756, objectId=8eb0134e56d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eb0134e56d7, replyNumber=0, likeNumber=23, createdTime=2018-04-12, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eb0134e56d7, moduleTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eb0134e56d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631071, encodeId=7efe16310e15e, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定, objectType=article, longId=88077, objectId=d1a0880e7c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1a0880e7c8, replyNumber=0, likeNumber=40, createdTime=2017-01-27, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1a0880e7c8, moduleTitle=Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1a0880e7c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631070, encodeId=7d8916310e0ba, content=<a href='/topic/show?id=921a385567' target=_blank style='color:#2F92EE;'>#B细胞非霍奇金淋巴瘤#</a>, objectTitle=TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂, objectType=article, longId=87833, objectId=1fe48e83325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fe48e83325, replyNumber=0, likeNumber=36, createdTime=2017-01-21, rootId=0, userName=photoman, userId=306221667512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fe48e83325, moduleTitle=TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fe48e83325)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞非霍奇金淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T细胞# #B细胞非霍奇金淋巴瘤# #大 B 细胞淋巴瘤#

昨天发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤# #B-NHL#

柳叶刀重磅综述：B细胞非霍奇金淋巴瘤

2024-04-17发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤# #CAR-T细胞治疗# #B细胞非霍奇金淋巴瘤#

Mol Cancer：新型CAR-T细胞治疗AT101治疗复发或难治性B细胞非霍奇金淋巴瘤，客观缓解率91.7%！

2024-01-11发表于加利福尼亚

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究

2022-06-04

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR

2022-05-16

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2021-09-12

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性

2021-03-22

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析

2020-06-06

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展

2020-04-08

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

Lancet：R-CHOP化疗联合利妥昔单抗治疗侵袭性B细胞非霍奇金淋巴瘤

2019-12-22

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

AP&T：慢性乙型肝炎会增加B细胞非霍奇金淋巴瘤和多发性骨髓瘤发生风险

2019-02-18

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好

2018-04-12

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定

2017-01-27

photoman (审核中...)

前往app查看评论内容

#B细胞非霍奇金淋巴瘤#

TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂

2017-01-21

科室
- - 订阅+
  - 更多科室
工具
服务